Marsh & McLennan Companies, Inc. (NYSE: MMC) has come under some pressure over the past year, falling to about $177/share from highs near $248. The decline mostly reflects broader market volatility rather than business weakness. The company remains a steady performer, backed by resilient client demand in insurance brokerage and consulting.
Recently, Marsh reported third-quarter results showing solid growth across both its insurance and consulting segments. The Risk and Insurance Services division continued to perform well, while Oliver Wyman posted higher revenue driven by steady client demand. Earlier this year, the company also raised its quarterly dividend, reflecting management’s confidence in its long-term earnings strength.
This article explores where Wall Street analysts think Marsh & McLennan could trade by 2027. We have pulled together consensus price targets and TIKR’s Guided Valuation Model to outline the stock’s potential path. These figures reflect analyst expectations, not TIKR’s own forecasts.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Modest Upside
Marsh & McLennan trades near $177/share today. The average analyst price target sits around $214/share, suggesting about 21% upside. Forecasts show a fairly tight range, signaling cautious optimism:
- High estimate: ~$258/share
- Low estimate: ~$181/share
- Median target: ~$211/share
- Ratings: 4 Buys, 2 Outperforms, 14 Holds, 1 Underperform, 1 Sell
Analysts see modest upside from here. Sentiment reflects confidence in the company’s fundamentals but not much expectation for multiple expansion. For investors, this suggests MMC may outperform in stable markets but could struggle to break out meaningfully unless earnings growth accelerates.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
Marsh & McLennan: Growth Outlook and Valuation
The company’s fundamentals remain solid and predictable:
- Revenue is expected to grow about 6–7% annually through 2027
- Operating margins could expand toward 27%
- Shares trade near 18× forward earnings, slightly below historical averages
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 17.5× forward P/E suggests ~$215/share by 2027
- That implies roughly 21% total upside, or around 9.5% annualized returns
These figures show that Marsh’s value lies in consistent execution rather than aggressive growth. The valuation already prices in its reputation as a dependable compounder, leaving limited room for a major re-rating.
For investors, Marsh & McLennan looks like a stable, high-quality holding that can deliver steady returns through reliable earnings growth and disciplined capital management.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
Marsh & McLennan remains one of the most reliable names in professional services. Its insurance brokerage business continues to benefit from strong pricing trends and high client retention, while Oliver Wyman is expanding into higher-margin areas like sustainability, risk management, and digital transformation.
Management’s focus on cost efficiency and consistent capital returns also adds to the appeal. For investors, these strengths point to durable earnings growth and predictable cash flow, making MMC a dependable compounder even in slower markets.
Bear Case: Valuation and Growth Constraints
Despite its strong fundamentals, Marsh’s valuation leaves limited room for a major re-rating. The stock already trades near fair value relative to peers, and growth is expected to remain steady rather than accelerating.
A slowdown in insurance pricing or weaker corporate consulting demand could pressure results. For investors, the main risk is that Marsh’s predictable growth may also mean predictable returns, solid but not spectacular, if the broader economy softens.
Outlook for 2027: What Could MMC Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model suggests Marsh & McLennan could trade near $215/share by 2027, representing about 21% total upside and 9.5% annualized returns from current levels around $177/share.
While that outlook shows steady compounding potential, it already assumes continued margin strength and moderate growth. To unlock greater upside, Marsh would need stronger consulting expansion or sustained pricing tailwinds in its insurance segment.
For investors, Marsh & McLennan stands out as a dependable, high-quality business built for long-term compounding rather than quick gains, a company that delivers quiet consistency year after year.
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
